Announced Tue, 25 Aug, 2026 · 18:36 IST
Subsidiary renews Australia OTC supply deal worth Rs 204 Cr
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹530.00
prior close
₹576.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.6-5.2-5.6-6.2-1.6-1.2-1.7-2.1-2.5-2.3-4.0-4.0——
Up moveDown movePending
AI summary
Sai Parenterals' subsidiary Noumed Pharmaceuticals renewed a 3-year OTC medicines supply agreement with a leading Australian pharmacy chain. Deal value projected at AUD 30 million, about Rs 204 Crores at Rs 68.52 per AUD. Effective 24 August 2026, with expanded product portfolio and higher value than the prior agreement.
Likely market impact
Strengthens export revenue visibility over 3 years and signals deeper Australia OTC market penetration.